ImmunityBio has launched a Phase 1 trial, known as QUILT 106, in South Africa to investigate its CD19 t-haNK cell therapy for the treatment of non-Hodgkin lymphoma. This marks ImmunityBio's first natural killer cell-based trial in the region, with the goal of enrolling up to 100 patients by early 2025.
The QUILT 106 study will assess the CD19 t-haNK cell therapy both as a standalone treatment and in combination with rituximab. The trial is designed to deliver innovative cancer treatments to a patient population often underrepresented in advanced research. Patrick Soon-Shiong, ImmunityBio's executive chairman, emphasized the trial's significance in addressing unmet medical needs in Sub-Saharan Africa, potentially setting a precedent for future research in underserved areas.
Targeting Liquid Tumors with Novel CAR-NK Technology
ImmunityBio's strategy involves leveraging CAR-NK technology to address gaps where existing therapies for liquid tumors have limitations. The company aims to generate critical data by the second half of 2025, which could potentially reshape cancer treatment approaches. The trial's design reflects a growing confidence in ImmunityBio's approach to cancer therapy, particularly in targeting liquid tumors with a novel approach.
Financial Outlook and Market Response
The launch of the Phase 1 trial has been met with positive market response, with ImmunityBio's stock price surging. EF Hutton has set a price target of $30 for ImmunityBio, suggesting a potential 357% increase from current levels. This target reflects investor confidence in ImmunityBio's expanding pipeline and its potential to disrupt the cancer therapy space.
